Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...

Recursion uses artificial intelligence to help advance drug discovery, which could be a massive opportunity in healthcare.

Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...

Co-Founder and CEO Chris Gibson to Transition to Chairman of the Board; Najat Khan to be named Chief Executive Officer and PresidentSalt Lake City, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Recursion ...

Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...

Salt Lake City, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in ...

Learn how Claude's ability to monitor its internal states could transform AI safety and provide insights into human brain ...

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.

Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

If language is what makes us human, what does it mean now that large language models have gained “metalinguistic” abilities?

In this week’s edition of InnovationRx, we look Nvidia’s collaborations in life sciences and drug development, Cobot’s ...

Within the peer analysis summary, vital metrics for Agios Pharmaceuticals, Recursion Pharmaceuticals and Apellis ...